Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | TSHR | P16473 | 4/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22648282 | 0.79 | TDP1 (0.56) | TDP1ALDH1A1TSHRHSD17B10ALOX15 | |
| SCHEMBL841689 | 0.78 | TDP1 (0.70) | TDP1ALDH1A1TSHRHSD17B10ALOX15 | |
| SCHEMBL66892 | 0.78 | TDP1 (1.00) | TDP1ALDH1A1TSHRHSD17B10ALOX15 | |
| SCHEMBL990038 | 0.78 | TDP1 (0.70) | TDP1ALDH1A1TSHRHSD17B10ALOX15 | |
| SCHEMBL18559184 | 0.77 | MAPT (0.50) | TDP1ALDH1A1TSHRHSD17B10ALOX15 | |
| SCHEMBL22648059 | 0.77 | TDP1 (0.54) | TDP1ALDH1A1TSHRHSD17B10ALOX15 | |
| SCHEMBL23319717 | 0.76 | TDP1 (0.94) | TDP1ALDH1A1TSHRHSD17B10ALOX15 | |
| SCHEMBL22710108 | 0.76 | TDP1 (0.67) | TDP1ALDH1A1TSHRHSD17B10ALOX15 | |
| Hydrochloric Acid SCHEMBL7407338 | 0.76 | TDP1 (0.94) | TDP1ALDH1A1TSHRHSD17B10ALOX15 | |
| SCHEMBL15212378 | 0.76 | TDP1 (0.94) | TDP1ALDH1A1TSHRHSD17B10ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11813295-B1 | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity | Theobald Therapeutics LLC (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230136150-A1 | Compositions for Inhibition of Insect Sensing | UNIV VANDERBILT (US) | 2023-05-04 | — | — | US | disclosed |
| US-10828356-B1 | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity | BERMUDES DAVID GORDON (US) | 2020-11-10 | — | — | US | disclosed |
| US-10729731-B1 | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity | BERMUDES DAVID GORDON (US) | 2020-08-04 | — | — | US | disclosed |
| US-20200199081-A1 | STK19 INHIBITORS FOR TREATMENT OF CANCER | TRUSTEES OF BOSTON UNIVERSITY (US) | 2020-06-25 | — | — | US | disclosed |
| US-10449237-B1 | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity | BERMUDES DAVID GORDON (US) | 2019-10-22 | — | — | US | disclosed |
| US-10286051-B1 | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity | BERMUDES DAVID GORDON (US) | 2019-05-14 | — | — | US | disclosed |
| US-20180177767-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2018-06-28 | — | — | US | disclosed |
| US-9616114-B1 | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity | BERMUDES DAVID GORDON (US) | 2017-04-11 | — | — | US | disclosed |
| US-9249181-B2 | C-terminal amidation of polypeptides | AMYLIN PHARMACEUTICALS, LLC (US) | 2016-02-02 | — | — | US | disclosed |
| WO-2012036962-A2 | C-TERMINAL AMIDATION OF POLYPEPTIDES | AMYLIN PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| US-20090030099-A1 | FOAM COMPOSITION AND FOAM | THE YOKOHAMA RUBBER CO., LTD. (JP) | 2009-01-29 | — | — | US | disclosed |
| EP-1724318-A1 | METHOD FOR ADHESIVE-BONDING VULCANIZED RUBBER COMPOSITIONS BY THE USE OF THERMOPLASTIC ELASTOMER COMPOSITIONS | THE YOKOHAMA RUBBER CO., LTD. (JP) | 2006-11-22 | — | — | EP | disclosed |
| US-20060213605-A1 | Method for adhesive-bonding vulcanized rubber compositions by the use of thermoplastic elastomer compositions | YOKOHAMA RUBBER CO., LTD., THE (JP) | 2006-09-28 | — | — | US | disclosed |
| US-20060199917-A1 | thermoplastic elastomer exhibiting high recyclability and oil resistance as well as excellent mechanical strength, and in particular, excellent resistance to compression set is provided. The thermoplastic resin with epoxy, hydroxy or nitrogen groups in backbone | YOKOHAMA RUBBER CO., LTD., THE (JP) | 2006-09-07 | — | — | US | disclosed |
| EP-1695987-A1 | Thermoplastic elastomer composition | THE YOKOHAMA RUBBER CO., LTD. (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-20060189755-A1 | Thermoplastic elastomer composition | THE YOKOHAMA RUBBER CO., LTD. | 2006-08-24 | — | — | US | disclosed |
| EP-0218548-B1 | CHROMOGENE QUINAZOLINE DERIVATIVES | CIBA-GEIGY AG (CH) | 1993-08-11 | — | — | EP | disclosed |
| US-4766211-A | FOR PRESSURE SENSITIVE OR HEAT SENSITIVE RECORDING MATERIALS; LIGHTFASTNESS | CIBA-GEIGY CORPORATION (US) | 1988-08-23 | — | — | US | disclosed |
| EP-0218548-A2 | Chromogene quinazoline derivatives | CIBA-GEIGY AG (CH) | 1987-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200199081-A1 | STK19 INHIBITORS FOR TREATMENT OF CANCER | STK11, CDK9, STK3 | TDP1 1099/4885ALDH1A1 2015/4885TSHR 3167/4885 |
| US-20230136150-A1 | Compositions for Inhibition of Insect Sensing | OR51E2, TRPA1, OR10J3 | TDP1 4502/4885ALDH1A1 3579/4885TSHR 2971/4885 |
| US-20180177767-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | TDP1 3096/4885ALDH1A1 4162/4885TSHR 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.